165 related articles for article (PubMed ID: 36858505)
41. Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.
Permana H; Soetedjo NNM; Yanto TA; Tendean M; Hariyanto TI; Suastika K
Expert Rev Endocrinol Metab; 2024; 19(1):89-98. PubMed ID: 38047423
[TBL] [Abstract][Full Text] [Related]
42. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
43. Imeglimin Ameliorates β-Cell Apoptosis by Modulating the Endoplasmic Reticulum Homeostasis Pathway.
Li J; Inoue R; Togashi Y; Okuyama T; Satoh A; Kyohara M; Nishiyama K; Tsuno T; Miyashita D; Kin T; Shapiro AMJ; Chew RSE; Teo AKK; Oyadomari S; Terauchi Y; Shirakawa J
Diabetes; 2022 Mar; 71(3):424-439. PubMed ID: 34588186
[TBL] [Abstract][Full Text] [Related]
44. Imeglimin in type 2 diabetes.
Huston J; Schaffner H; Langley L; Skrable B; Ashchi A; Berner J; Gore A; Sheikh-Ali M; Sutton D; Goldfaden R
Drugs Today (Barc); 2022 Sep; 58(9):437-449. PubMed ID: 36102904
[TBL] [Abstract][Full Text] [Related]
45. Current understanding of imeglimin action on pancreatic β-cells: Involvement of mitochondria and endoplasmic reticulum homeostasis.
Fauzi M; Murakami T; Yabe D; Inagaki N
J Diabetes Investig; 2023 Feb; 14(2):186-188. PubMed ID: 36453164
[TBL] [Abstract][Full Text] [Related]
46. Antidiabetic compounds 8a, 8b, 8k, and 9h enhance insulin secretion: activity and mechanism.
Li H; Zhang J; Fu Y; Zhang Y; Zhang C; Sun X; Wu F; He J
Endocrine; 2021 Feb; 71(2):365-377. PubMed ID: 33219494
[TBL] [Abstract][Full Text] [Related]
47. Recent advances in understanding the anti-diabetic actions of dietary flavonoids.
Babu PV; Liu D; Gilbert ER
J Nutr Biochem; 2013 Nov; 24(11):1777-89. PubMed ID: 24029069
[TBL] [Abstract][Full Text] [Related]
48. Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan.
Katsuyama H; Hakoshima M; Heshiki T; Iida S; Adachi H; Yanai H
Diabetes Res Clin Pract; 2024 Jun; 213():111752. PubMed ID: 38908549
[TBL] [Abstract][Full Text] [Related]
49. Mitochondrial Dysfunction and Imeglimin: A New Ray of Hope for the Treatment of Type-2 Diabetes Mellitus.
Swain J; Jadhao P; Sravya SL; Teli B; Lavanya K; Singh J; Sahoo A; Das S
Mini Rev Med Chem; 2023 Oct; ():. PubMed ID: 37861052
[TBL] [Abstract][Full Text] [Related]
50. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
Clémence C; Fouqueray P; Sébastien B
Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063
[TBL] [Abstract][Full Text] [Related]
51. Mitochondrial Superoxide Production Decreases on Glucose-Stimulated Insulin Secretion in Pancreatic β Cells Due to Decreasing Mitochondrial Matrix NADH/NAD
Plecitá-Hlavatá L; Engstová H; Holendová B; Tauber J; Špaček T; Petrásková L; Křen V; Špačková J; Gotvaldová K; Ježek J; Dlasková A; Smolková K; Ježek P
Antioxid Redox Signal; 2020 Oct; 33(12):789-815. PubMed ID: 32517485
[No Abstract] [Full Text] [Related]
52. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
[No Abstract] [Full Text] [Related]
53. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.
Detaille D; Vial G; Borel AL; Cottet-Rouselle C; Hallakou-Bozec S; Bolze S; Fouqueray P; Fontaine E
Cell Death Discov; 2016; 2():15072. PubMed ID: 27551496
[TBL] [Abstract][Full Text] [Related]
54. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
55. Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.
Hagi K; Kochi K; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2024 May; ():. PubMed ID: 38794986
[TBL] [Abstract][Full Text] [Related]
56. Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach.
Alamer AA; Alsaleh NB; Aodah AH; Alshehri AA; Almughem FA; Alqahtani SH; Alfassam HA; Tawfik EA
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111693
[TBL] [Abstract][Full Text] [Related]
57. Integration of network and experimental pharmacology to decipher the antidiabetic action of Duranta repens L.
Khanal P; Patil BM
J Integr Med; 2021 Jan; 19(1):66-77. PubMed ID: 33071211
[TBL] [Abstract][Full Text] [Related]
58. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
[TBL] [Abstract][Full Text] [Related]
59. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
60. Glucose-mediated insulin secretion is improved in FHL2-deficient mice and elevated FHL2 expression in humans is associated with type 2 diabetes.
Habibe JJ; Clemente-Olivo MP; Scheithauer TPM; Rampanelli E; Herrema H; Vos M; Mieremet A; Nieuwdorp M; van Raalte DH; Eringa EC; de Vries CJM
Diabetologia; 2022 Oct; 65(10):1721-1733. PubMed ID: 35802167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
